Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data
1996

Mathematical Model for Enzyme-Conjugated Antibodies in Cancer Treatment

publication Evidence: moderate

Author Information

Author(s): LT Baxter, RK Jain

Primary Institution: Massachusetts General Hospital and Harvard Medical School

Hypothesis

Can a mathematical model improve the understanding of drug distribution in cancer therapy using enzyme-conjugated antibodies?

Conclusion

The model suggests that longer time delays and effective clearance of antibodies can enhance the efficacy of prodrug therapy in tumors.

Supporting Evidence

  • The model indicates that enzyme-conjugated antibodies can provide more uniform drug distribution in tumors.
  • Longer time delays between injections improve drug concentration in tumors.
  • Lower enzyme conversion rates can enhance the therapeutic index of the treatment.

Takeaway

Scientists created a computer model to help understand how special drugs can better reach cancer cells, making treatment more effective.

Methodology

A mathematical model was developed to analyze drug distribution using enzyme-conjugated antibodies and prodrugs, incorporating diffusion and reaction equations.

Limitations

The model assumes homogeneous transport properties and simplified plasma pharmacokinetics, which may not reflect real tumor environments.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication